Alnylam Pharmaceuticals
ALNY
330 hedge funds and large institutions have $11.8B invested in Alnylam Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 121 increasing their positions, 96 reducing their positions, and 33 closing their positions.
61% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 33
26% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 96
15% more call options, than puts
Call options by funds: $154M | Put options by funds: $134M
5% more funds holding
Funds holding: 315 → 330 (+15)
1.01% more ownership
Funds ownership: 94.95% → 95.96% (+1%)
4% less capital invested
Capital invested by funds: $12.3B → $11.8B (-$441M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$121M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$108M |
| 3 |
BlackRock
New York
|
+$62.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$40.9M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$231M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$106M |
| 3 |
Rockefeller Capital Management
New York
|
-$18.6M |
| 4 |
Dodge & Cox
San Francisco,
California
|
-$18.2M |
| 5 |
Morgan Stanley
New York
|
-$18M |
ALNY Hedge Fund Activity: Q1 2020 in Review
330 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2020, worth a combined $11.8B — down 3.6% from $12.3B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ALNY positions and 33 closed out — a net gain of 20 holders — while 121 added to existing stakes and 96 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $121M. The largest seller was Wellington Management Group, cutting an estimated $231M.
- 330 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2020, up from 315 in Q4 2019.
- Funds reported $11.8B of Alnylam Pharmaceuticals stock for Q1 2020, down 3.6% quarter-over-quarter.
- 53 funds opened new Alnylam Pharmaceuticals positions in Q1 2020 and 33 closed out, a net change of +20 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2020 was Manulife (Manufacturers Life Insurance), an estimated $121M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2020 was Wellington Management Group, an estimated $231M sold.
Based on aggregated 13F filings for Q1 2020.